SEARCH

SEARCH BY CITATION

References

  • 1
    Todo S, Demetris AJ, van Thiel D, Teperman L, Fung J, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus related liver disease. Hepatology 1991; 13:619.
  • 2
    O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus re-infection after orthotopic liver transplantationSerological and clinical implications. J Hepatol 1992; 14:104.
  • 3
    Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. New Engl J Med 1993; 329:1842.
  • 4
    Shouval D, Samuel D. Hepatitis B immune globulin to prevent HBV graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32:1189.
  • 5
    Feray C, Zignego AL, Samuel D, et al. Persistent hepatitis B virus infection of mononuclear cells without concomitant liver infection: transplantation model. Transplantation 1990; 49:1155.
  • 6
    Lauchart W, Muller R, Pichlmayr R. Long-term immunoprophylaxis of hepatitis B virus (HBV) re-infection in recipients of human liver allografts. Transplant Proc 1987; 19:4051.
  • 7
    Samuel D, Bismuth A, Mathieu D, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337:813.
  • 8
    Roche B, Feray C, Gigou M, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis. Hepatology 2003; 38:86.
  • 9
    Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulins. Hepatology 1996; 24:1327.
  • 10
    Lerut JP, Donataccio M, Ciccarelli O, et al. Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis. J Hepatol 1999; 30:706.
  • 11
    Blumhardt G, Neuhaus WD, Bechstein L, et al. Liver transplantation in HBsAg positive patients. Transplant Proc 1990; 22:1577.
  • 12
    Muller R, Gubernatis G, Farle M, et al. Liver transplantation in HBs antigen (HBsAg) carriersPrevention of hepatitis B virus (HBV) recurrence by passive immunisation. J Hepatol 1991; 13:90.
  • 13
    Lemmens HP, Langrehr JM, Blumhardt G, et al. Outcome following orthotopic liver transplantation in HBsAg positive patients using short or long-term immunoprophylaxis. Transplant Proc 1994; 26:3622.
  • 14
    Devlin J, Smith HM, O'Grady JG, Portmann B, Tan KC, Williams R. Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients. J Hepatol 1994; 21:204.
  • 15
    Koenig V, Hopf U, Neuhaus P, et al. Long-term follow up of hepatitis B virus infected recipients after orthotopic liver transplantation. Transplantation 1994; 58:553.
  • 16
    McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61:1358.
  • 17
    Gugenheim J, Crafa F, Fabiani P, et al. Récidive du virus de 1′hépatite B après transplantation hépatique. Gastroenterol Clin Biol 1992; 16:430.
  • 18
    Sawyer RG, McGory RW, Gaffey MJ, et al. Improved clinical outcome with liver transplantation for hepatitis B related cirrhosis. Ann Surg 1998; 227:841.
  • 19
    Nymann T, Shokouh-Amiri MH, Vera SR, Riely CA, Alloway RR, Gaber AO. Prevention of hepatitis B recurrence with indefinite hepatitis B immune globulin (HBIG) prophylaxis after liver transplantation. Clin Transplant 1996; 10:663.
  • 20
    Marcellin P, Samuel D, Areias .T, et al. Pretransplant interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease. Hepa-tology 1994; 19:6.
  • 21
    Tchervenkov J, Tector A, Barkun J, et al. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin post-transplant. Ann Surg 1997; 226:356.
  • 22
    DeMan RA, Marcellin P, Habal F, et al. A randomized placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. Hepatology 2000; 32:413.
  • 23
    Singh N, Gayowski T, Wannstedt CF, Wagener MM, Marino IR. Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplantation 1997; 63:1415.
  • 24
    Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28:585.
  • 25
    Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for de-compensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31:207.
  • 26
    Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33:301.
  • 27
    Kapoor D, Guptan RC, Wakil SM, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000; 33:308.
  • 28
    Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after transplantation for chronic hepatitis B. Hepatology 2001; 33:424.
  • 29
    Yao FY, Terrault NA, Freise C, Ma-slow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34:411.
  • 30
    Fontana R, Keeffe E, Carey W, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002; 8: 433.
  • 31
    Fontana R, Hann H, Perrillo R, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123:719.
  • 32
    Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129.
  • 33
    Schiff E, Lai CL, Neuhaus P, et al. Adefovir dipivoxil for the treatment of chronic hepatitis B in patients pre- and post-liver transplantation with lamivudine-resistant hepatitis B virus. Hepatology 2002; 36:371 A.
  • 34
    Stärkel P, Horsmans Y, Geubel A, et al. Favorable outcome of orthotopic liver transplantation in a patient with sub-acute liver failure due to emergence of a hepatitis B YMDD escape mutant virus. J Hepatol 2001; 35:679.
  • 35
    Saab S, Kim M, Wright T, et al. Successful orthotopic liver transplantation for lamivudine associated YMDD mutant hepatitis B virus. Gastroenterology 2000; 119:1382.
  • 36
    Rosenau J, Bahr M, Tillmann HL, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantationPossible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34:895.
  • 37
    Seehofer D, Rayes N, Naumann U, et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA-positive patients undergoing liver transplantation. Transplantation 2001; 72:1381.
  • 38
    Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348:1212.
  • 39
    Mutimer D, Dusheiko G, Barrett C, et al. Lamivudine without HBIG for prevention of graft reinfection by hepatitis B: long-term follow up. Transplantation 2000; 70:809.
  • 40
    Lo CM, Cheung ST, Lai, et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001; 233:276.
  • 41
    Malkan G, Cattral M, Humar A, et al. Lamivudine for hepatitis B in liver transplantation. Transplantation 2000; 69:1403.
  • 42
    Mutimer D, Pillay D, Shields P, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46:107.
  • 43
    Lo C, Fung J, Lau G, et al. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 2003; 37:36.
  • 44
    Marzano A, Salizzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34:903.
  • 45
    Yao FY, Osorio RW, Roberts JP, et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999; 5:491.
  • 46
    Yoshida EM, Erb SR, Partovi N, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5:520.
  • 47
    Angus PW, McCaughan GW, Gane EJ, Crawford DHG, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6:429.
  • 48
    McCaughan GW, Spencer J, Koorey D, Bowden S, Bartholomeusz A, Littlejohn M. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precoce mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999; 6:512.
  • 49
    Han SH, Ofman J, Holt C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin mono-therapy. Liver Transpl 2001; 6:741.
  • 50
    Roche B, Samuel D, Roque AM, et al. Intravenous anti-HBs Ig combined with oral lamivudine for prophylaxis against HBV recurrence after liver transplantation (abstract). J Hepatol 1999; 30:A80.
  • 51
    Gane EJ, McCaughan G, Crawford D, et al. Combination lamivudine plus low dose intramuscular hepatitis B immunoglobulin prevents recurrent hepatitis B and may eradicate residual graft infection. Hepatology 2002; 36:221A.
  • 52
    Han SH, Martin P, Edelstein M, et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003; 9:182.
  • 53
    Sanchez-Fueyo A, Rimola A, Grande L, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31:496.
  • 54
    Sanchez-Fueyo A, Martinez-Bauer E, Rimola A. Hepatitis B vaccination after liver transplantation. Hepatology 2002; 36:257.
  • 55
    Bienzle U, Gunther M, Neuhaus R, Neuhaus P. Successful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: preliminary results. Liver Transpl 2002; 8:562.
  • 56
    Angelico M, Di Paolo D, Trinito M, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002; 35:176.
  • 57
    Dodson SF, de Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000; 6:434.
  • 58
    Naoumov NV, Lopes AR, Burra P, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001; 34:888.
  • 59
    Buti M, Mas A, Prieto M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38:811.
  • 60
    Rizzetto M, Macagno S, Chiaberge E, et al. Liver transplantation in hepatitis delta virus disease. Lancet 1987; 11:469.
  • 61
    Samuel D, Zignego AL, Reynes M, et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis due to chronic delta hepatitis. Hepatology 1995; 21:333.
  • 62
    Manzarbeitia C, Reich D, Ortiz J, et al. Safe use of liver donors with positive hepatitis B core antibody. Liver Transpl 2002; 8:556.
  • 63
    Prieto M, Gomez MD, Berenguer M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001; 7:51.
  • 64
    Dickson R, Everhart J, Lake JR, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 1997; 113:1168.
  • 65
    Douglas D, Rakela J, Wright T, Krom R, Wiesner R. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997; 3:105.
  • 66
    Roche B, Samuel D, Gigou M, et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997; 26:517.
  • 67
    Uemoto S, Sugiyama K, Marusawa H, et al. Transmission of hepatitis B virus from core antibody positive donors in living related liver transplants. Transplantation 1998; 65:494.
  • 68
    Dodson S, Bonham C, Geller D, Cacciarelli T, Rakela J, Fung J. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti HBc-positive donors. Transplantation 1999; 68:1058.
  • 69
    Yu AS, Vierling J, Colquhoun S, et al. Transmission of hepatitis B virus infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001; 7:513.
  • 70
    Terrault NA, Combs Holland C, Ferrell L, et al. Interferon alpha for recurrent hepatitis B infection after liver transplantation. Liver Transpl Surg 1996; 2:132.
  • 71
    Gish RG, Lau JYN, Brooks L, et al. Ganciclovir treatment of hepatitis B virus (HBV) infection in liver transplant patients. Hepatology 1996; 23:1.
  • 72
    Roche B, Samuel D, Gigou M, et al. Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation. J Hepatol 1999; 31:584.
  • 73
    Rayes N, Seehofer D, Hopf U, et al. Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation. Transplantation 2001; 71:96.
  • 74
    Perrillo R, Rakela J, Dienstag J, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29:1581.
  • 75
    Roche B, Samuel D, Roque AM, et al. Lamivudine therapy for HBV infection after liver transplantation (abstract). J Hepatol 1999; 30:78.
  • 76
    Nery JR, Weppler D, Rodriguez M, Ruiz P, Schiff ER, Tzakis AG. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 1998; 65:1615.
  • 77
    Ben-Ari Z, Mor E, Shapira Z, Tur-Ka-spa R. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl 2001; 7:113.
  • 78
    Andreone P, Caraceni P, Grazi GL, et al. Lamivudine treatment for acute hepatitis B after liver transplantation. J Hepatol 1998; 29:985.
  • 79
    Fischer L, Sterneck M, Zöllner B, Rogiers X. Lamivudine improves the prognosis of patients with hepatitis B after liver transplantation. Transplant Proc 2000; 32:2128.
  • 80
    Malkan G, Cattral M, Humar A, et al. Lamivudine for hepatitis B in liver transplantation. Transplantation 2000; 69:1403.
  • 81
    Fontana RJ, Hann HW, Wright T, et al. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001; 6:504.
  • 82
    Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27:1711.
  • 83
    Bock CT, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122:264.
  • 84
    Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129.
  • 85
    Peters MG, Singer G, Howard T, et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on Adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999; 68:1912.
  • 86
    Mutimer D, Feraz-Neto BH, Harrison R, et al. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 2001; 49:860.
  • 87
    Walsh KM, Woodall T, Lamy P, et al. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001; 49:436.
  • 88
    Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125:292.
  • 89
    Shakil AO, Lilly L, Angus P, Gerken G, Thomas N. Entecavir reduces viral load in liver transplant patients who have failed prophylaxis or treatment for hepatitis B (abstract). Hepatology 2001; 34[Suppl]:619.
  • 90
    van Bommel F, Wunsche T, Schur-mann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002; 36:507.
  • 91
    Crippin J, Foster B, Carlen S, Borcich A, Bodenheimer H. Retransplantation in hepatitis B–a multicenter experience. Transplantation 1994; 57:823.
  • 92
    Roche B, Samuel D, Feray C, et al. Retransplantation of the liver for recurrent hepatitis B virus infection: the Paul Brousse experience. Liver Transpl Surg 1999; 5:166.
  • 93
    Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35:1528.